In a landmark development for the European life sciences sector, Netherlands-based venture capital firm Forbion has successfully closed a massive €2.3 billion ($2.6 billion) fundraising round. This infusion of capital, split across two distinct investment vehicles—Forbion Growth Opportunities IV and Forbion Ventures Fund VIII—marks the firm’s largest financial mobilization to date. By providing a substantial injection of "dry powder" into a market currently starved of liquidity, Forbion is positioning itself as the primary firewall against the waning competitiveness of the European biotech ecosystem.
The announcement comes at a critical juncture. While global pharmaceutical innovation continues to accelerate, Europe has found itself increasingly marginalized compared to the powerhouse engines of the United States and China. Forbion’s success, therefore, is being viewed not just as a victory for a single firm, but as a potential turning point for an entire continent struggling to retain its scientific talent and research infrastructure.
The Mechanics of the Raise: Scaling for Impact
The sheer scale of the €2.3 billion raise underscores a deliberate strategy by Forbion to bridge the "valley of death" that often claims promising startups before they reach clinical maturity. With the capacity to support as many as 30 young companies, the firm is moving quickly to deploy capital.
Recent investments already reflect the strategic focus of these new funds. Forbion has taken notable positions in companies such as Sling Therapeutics and Solstice Oncology, demonstrating a continued commitment to high-growth, high-impact therapeutics. These investments are designed to provide the runway necessary for companies to progress through the notoriously expensive Phase 2 and Phase 3 clinical trials, where many European firms historically falter due to funding gaps.
The firm’s institutional backing for this round includes some of the most influential names in the European and global investment landscape. Dutch pension giants MN and PGGM, the Kauffman Foundation, Germany’s state-backed KfW Capital, and pharmaceutical heavyweight Eli Lilly have all contributed. With this latest injection, Forbion’s total assets under management (AUM) have swelled to approximately €7.5 billion, solidifying its status as Europe’s premier venture capital firm exclusively dedicated to the life sciences.
A Chronology of Growth: From Startup Backer to Market Titan
Forbion’s trajectory has been one of consistent, aggressive expansion. Since its inception, the firm has supported 142 distinct companies, a portfolio that has successfully shepherded 21 medical products to market—a track record of commercial success that few European venture firms can match.
The Recent Exit Streak
The firm’s reputation has been burnished by a series of high-profile acquisitions and successful public offerings over the last few years. By acting as a kingmaker for early-stage innovation, Forbion has effectively fed the acquisition appetites of global pharmaceutical giants:
- Capstan Therapeutics: The firm’s support helped position this cell therapy developer as an attractive asset, eventually leading to its acquisition by AbbVie.
- Mariana Oncology: An example of Forbion’s prowess in the hot field of radiopharmaceuticals, Mariana was snapped up by Novartis.
- Aiolos Bio: A key investment that culminated in an acquisition by GSK, focusing on cutting-edge asthma treatment.
- MapLight Therapeutics: Demonstrating the firm’s ability to guide companies to the public markets, MapLight’s successful IPO remains a benchmark for Forbion’s portfolio management.
Between 2022 and late 2026, Forbion publicly disclosed at least 55 investments. This level of activity, corroborated by BioPharma Dive data, positions the firm as perhaps the most influential liquidity provider in the European biopharmaceutical sector, providing a stable backbone for innovation while others retreated to the sidelines.
Supporting Data: The Capital Deficit in European Biotech
The euphoria surrounding Forbion’s latest raise is tempered by the grim reality of the broader European market. While Forbion is thriving, the sector at large is signaling a distress code.
The disparity in capital allocation between regions is stark. In the United States, the availability of "venture debt" and late-stage growth capital is robust, supported by a mature ecosystem of specialized investors and public markets that are comfortable with the inherent volatility of biotech. In contrast, Europe has struggled with a fragmented regulatory environment and a conservative investment culture that often views drug development as a cost-sink rather than a value-creation engine.
According to industry reports, Europe’s share of global R&D spending has been in a slow but steady decline for over a decade. While government-backed initiatives exist, they often lack the agility and sheer volume of capital provided by US-based venture funds. Consequently, European startups that show early promise are frequently forced to migrate to the U.S. to complete their clinical trials or to seek acquisition by American firms, essentially exporting the economic benefits of their innovation.
Official Responses and Strategic Vision
Sander Slootweg, co-founder and managing partner of Forbion, acknowledged the harsh market realities during the fund announcement. "Our successful fundraising gives us significant dry powder in a market characterized by a general shortage of capital," Slootweg stated. His words reflect a pragmatic view of the landscape: Forbion is not merely investing for growth; it is stepping in to provide liquidity where traditional market mechanisms have failed.
However, the firm’s leadership is also aware that capital alone cannot solve the "European problem." There is a growing consensus that the structural environment in Europe must change if it is to remain a viable competitor to the United States and China.
Implications: A Continent at a Crossroads
The tension between scientific excellence and economic viability has reached a breaking point. Last month, an open letter signed by nine prominent board chairs of European biotech firms served as a blunt warning to policymakers. The executives argued that Europe has consistently treated medicine as a "cost to suppress" rather than an investment in human capital and economic future.
The implications of this neglect are becoming impossible to ignore:
- Clinical Trial Migration: Because of regulatory friction and funding hurdles, clinical trials are increasingly being relocated to China and the U.S., resulting in a loss of institutional knowledge and patient access to experimental therapies.
- The "Brain Drain": Top-tier scientific talent is increasingly looking toward the U.S. or China, where the resources to bring a drug from the lab bench to the pharmacy shelf are more readily available.
- Regulatory Flexibility: The executives pointed to China’s rapid rise as a result of government support and regulatory agility. Europe, by comparison, remains trapped in a bureaucratic labyrinth that adds years to the development cycle of life-saving treatments.
As the nine executives succinctly stated, "Europe’s alarm bells are ringing."
Forbion’s $2.6 billion raise is a monumental achievement, but it serves as a stopgap measure. It provides the fuel for the current engine, but it does not address the underlying design flaws of the European biotech vehicle. For the European industry to flourish, the success of firms like Forbion must be matched by a fundamental shift in government policy—moving from a posture of regulation and restriction to one of strategic support and investment.
For now, the sector holds its breath. Forbion has provided the capital, the leadership, and the platform. Whether this will be enough to reverse the tide and ensure that the next generation of life-saving breakthroughs are discovered, developed, and commercialized on European soil remains the defining question of the next decade. For investors, policymakers, and patients alike, the stakes could not be higher.
About the Author
